Insights

A century ago, political rallies were very different. Audiences would stand outside for hours, listening carefully as candidates explained their policies in detail.

Early diagnosis is one of the most powerful strategies in modern healthcare. Yet too often, fear, discomfort and stigma prevent people from taking part in traditional screening programmes.

Payer Perspectives on Global Implications for Pharmaceutical Markets and Patient Access

Most teams want to use AI. Few succeed. With 80% of projects failing to deliver value, learn how to close the gap between ambition and execution - and turn potential into patient impact.

As we step into 2026, it’s important to not only reflect on the challenges, but the triumphs of 2025.

Advances in genetic science are opening new possibilities in how we understand and treat disease. Among the most talked-about developments are gene therapy and gene editing - two approaches that hold the potential to modify, and potentially even cure, diseases by targeting their genetic roots.

The development of new medicines is an expensive and time-consuming process, so pharmaceutical companies need deep pockets and huge resources to see potential new treatments through to marketing authorisation.

In recent years, the healthcare landscape has been steadily moving towards more patient-centric models, focusing on convenience and quality of life.

As an increasing number of Advanced Therapy Medicinal Products (ATMPs), including CGTs, are seeking market authorisation, the growing costs of these therapies need to be managed by payers to ensure long-term access for patients in need.